Document Detail

Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
MedLine Citation:
PMID:  19446878     Owner:  NLM     Status:  MEDLINE    
Imatinib-induced macrocytic anemia was known to result from c-kit inhibition in chronic myeloid leukemia (CML). However, recent studies showed that the prevalence of anemia is increased with high trough imatinib level and increased doses of imatinib influence decreased proliferation of burst forming units-erythroids (BFU-Es). The aim of this study was to evaluate the continuously increased mean cell volume (MCV) level's correlation with cytogenetic response and the favorable outcome in early chronic phase (CP)-CML patients. Clinical importance of MCV level was evaluated to correlate with cytogenetic response and compared with Sokal score, a known excellent prognostic parameter of cytogenetic response (CCR) in 84 early CP-CML patients. The patients with early and continuously increased MCV level irrespective of anemia achieved higher CCR after 12 months of imatinib therapy than patients with non-CCR (p=0.011). When the value was compared with low Sokal score, elevated MCV was independent predictor of CCR (RR=12.925, p=0.002 vs. RR=35.445, p<0.001). Furthermore, the patients with early and continuously increased MCV level had a higher probability of maintaining CCR than non-increased level (p=0.019). Increased MCV level was surrogate marker of achievement and durability to CCR for early CP-CML patients in the present study.
Moo-Kon Song; Joo-Seop Chung; Young-Mi Seol; Seong-Geun Kim; Ho-Jin Shin; Young-Jin Choi; Goon-Jae Cho
Related Documents :
1703118 - Haematological complications in polycythaemia vera and thrombocythaemia patients treate...
10829048 - Molecular remission after allogeneic or autologous transplantation of hematopoietic ste...
12592328 - Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-cd33 mon...
8275458 - Comparison of clinical and biologic features between myeloid and lymphoid transformatio...
21972848 - Factor viii deficiency does not protect against atherosclerosis.
9079438 - Combined stereotactic thalamotomy and posteroventral pallidotomy for parkinson's disease.
Publication Detail:
Type:  Journal Article     Date:  2009-05-15
Journal Detail:
Title:  Leukemia research     Volume:  33     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-08-21     Completed Date:  2009-09-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1459-62     Citation Subset:  IM    
Department of Hematology-Oncology, Pusan National University Hospital Medical Research Institute, Busan, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Erythrocyte Indices*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy,  genetics,  pathology*
Middle Aged
Multivariate Analysis
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Retrospective Studies
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib
Comment In:
Leuk Res. 2009 Nov;33(11):1450-1   [PMID:  19615745 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.
Next Document:  Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymph...